Flatiron Health Announces Strategic Partnership with Massive Bio to Enhance Patient Identification Capabilities and Services
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Flatiron Health, a healthtech company transforming clinical research through technology that integrates research into everyday care, today announced a strategic partnership with Massive Bio, global leader in using artificial intelligence to streamline patient identification and recruitment for clinical trials, to expand patient identification capabilities and improve clinical trial enrollment across the U.S.“Flatiron Health is excited to join forces with Massive Bio, combining expertise and resources to advance personalized treatment options for cancer patients,” said Michael Bierl, Vice President, Clinical Research Partnerships and General Manager, Europe, Flatiron Health. “By leveraging Massive Bio’s robust network and database, we can continue to utilize our cutting edge tools to empower sites to progress research, enhance workflows and efficiencies, accelerate clinical trace pace while ensuring diverse patient populations have access to life-changing
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA approves Roche's Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular LymphomaBusiness Wire
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance]Yahoo! Finance
- Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships? [Yahoo! Finance]Yahoo! Finance
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance Canada]Yahoo! Finance Canada